These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26093227)

  • 1. Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too.
    Kosehasanogullari G; Ozakbas S; Idiman E
    Clin Neurol Neurosurg; 2015 Sep; 136():107-9. PubMed ID: 26093227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.
    Guimarães I; Cardoso MI; Sá MJ
    Mult Scler; 2006 Jun; 12(3):354-6. PubMed ID: 16764350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
    Brettschneider J; Petzold A; Junker A; Tumani H
    Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis.
    Terzi M; Birinci A; Cetinkaya E; Onar MK
    Acta Neurol Scand; 2007 May; 115(5):325-30. PubMed ID: 17489943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.
    Bartosik-Psujek H; Archelos JJ
    J Neurol; 2004 Apr; 251(4):414-20. PubMed ID: 15083285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis.
    Brettschneider J; Maier M; Arda S; Claus A; Süssmuth SD; Kassubek J; Tumani H
    Mult Scler; 2005 Jun; 11(3):261-5. PubMed ID: 15957504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.
    Szalardy L; Zadori D; Simu M; Bencsik K; Vecsei L; Klivenyi P
    J Neurol Sci; 2013 Aug; 331(1-2):38-42. PubMed ID: 23706476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 14-3-3 protein in multiple sclerosis: a marker of disease severity.
    Colucci M; Roccatagliata L; Capello E; Narciso E; Latronico N; Tabaton M; Mancardi GL
    Mult Scler; 2004 Oct; 10(5):477-81. PubMed ID: 15471360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cerebrospinal fluid tau protein in multiple sclerosis.
    Kapaki E; Paraskevas GP; Michalopoulou M; Kilidireas K
    Eur Neurol; 2000; 43(4):228-32. PubMed ID: 10828654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
    Albanese M; Zagaglia S; Landi D; Boffa L; Nicoletti CG; Marciani MG; Mandolesi G; Marfia GA; Buttari F; Mori F; Centonze D
    J Neuroinflammation; 2016 Feb; 13():36. PubMed ID: 26863878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.
    Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K
    JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.
    Valis M; Talab R; Stourac P; Andrys C; Masopust J
    Neuro Endocrinol Lett; 2008 Dec; 29(6):971-6. PubMed ID: 19112391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis.
    Jiménez-Jiménez FJ; Zurdo JM; Hernanz A; Medina-Acebrón S; de Bustos F; Barcenilla B; Sayed Y; Ayuso-Peralta L
    Acta Neurol Scand; 2002 Dec; 106(6):351-4. PubMed ID: 12460140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau protein: a possible prognostic factor in optic neuritis and multiple sclerosis.
    Frederiksen J; Kristensen K; Bahl JM; Christiansen M
    Mult Scler; 2012 May; 18(5):592-9. PubMed ID: 21969238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients.
    Rommer PS; Kamin F; Petzold A; Tumani H; Abu-Mugheisib M; Koehler W; Hoffmann F; Winkelmann A; Benecke R; Zettl UK
    Mol Diagn Ther; 2014 Dec; 18(6):631-7. PubMed ID: 24986188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.
    Martínez-Yélamos A; Saiz A; Bas J; Hernandez JJ; Graus F; Arbizu T
    Neurosci Lett; 2004 Jun; 363(1):14-7. PubMed ID: 15157986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.